Ads
related to: vasopressin mechanism of action cardiac arrest- Things You Should Know
View Important Safety Information.
Heart Failure Facts & Information.
- Patient Coverage
Pay As Little As $10.
Search For Patient Coverage.
- Coverage
Lowest Branded Copay Access.
Search For Coverage In Your Area.
- Resources
Resources For You And Your Staff.
Resources For You & Your Patients.
- Hospital Results
Outcomes In The Hospital Setting.
Learn About Management Guideline.
- Safety Data
Safety & Warning Info For HCPs.
Review Clinical Trail Data On HF.
- Things You Should Know
wexnermedical.osu.edu has been visited by 10K+ users in the past month
Search results
Results From The WOW.Com Content Network
Although both vasopressors, vasopressin and epinephrine differ in that vasopressin does not have direct effects on cardiac contractility as epinephrine does. [18] Thus, vasopressin is theorized to be of increased benefit over epinephrine in cardiac arrest due to its properties of not increasing myocardial and cerebral oxygen demands. [18]
551 11998 Ensembl ENSG00000101200 ENSMUSG00000037727 UniProt P01185 P35455 RefSeq (mRNA) NM_000490 NM_009732 RefSeq (protein) NP_000481 NP_033862 Location (UCSC) Chr 20: 3.08 – 3.08 Mb Chr 2: 130.42 – 130.42 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse Human vasopressin, also called antidiuretic hormone (ADH), arginine vasopressin (AVP) or argipressin, is a hormone synthesized ...
However, as many incidents of cardiac arrest occur out-of-hospital or when a person is not having their cardiac activity monitored, it is difficult to identify the specific mechanism in each case. Structural heart disease , such as coronary artery disease , is a common underlying condition in people who experience cardiac arrest.
The actions of vasopressin are mediated by stimulation of tissue-specific G protein-coupled receptors (GPCRs) called vasopressin receptors that are classified into the V 1 (V 1A), V 2, and V 3 (V 1B) receptor subtypes. [1] These three subtypes differ in localization, function and signal transduction mechanisms. [2]
Sympathomimetic drugs are used to treat cardiac arrest and low blood pressure, or even delay premature labor, among other things. These drugs can act through several mechanisms, such as directly activating postsynaptic receptors, blocking breakdown and reuptake of certain neurotransmitters, or stimulating production and release of catecholamines.
Conivaptan, sold under the brand name Vaprisol, is a non-peptide inhibitor of the receptor for anti-diuretic hormone, also called vasopressin. It was approved in 2004 for hyponatremia (low blood sodium levels). The compound was discovered by Astellas and marked in 2006. The drug is now marketed by Cumberland Pharmaceuticals, Inc.